167 related articles for article (PubMed ID: 18500563)
1. Application of the biopharmaceutical classification system in clinical drug development--an industrial view.
Cook J; Addicks W; Wu YH
AAPS J; 2008 Jun; 10(2):306-10. PubMed ID: 18500563
[TBL] [Abstract][Full Text] [Related]
2. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
[TBL] [Abstract][Full Text] [Related]
3. Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond.
Polli JE; Abrahamsson BS; Yu LX; Amidon GL; Baldoni JM; Cook JA; Fackler P; Hartauer K; Johnston G; Krill SL; Lipper RA; Malick WA; Shah VP; Sun D; Winkle HN; Wu Y; Zhang H
AAPS J; 2008 Jun; 10(2):373-9. PubMed ID: 18679807
[TBL] [Abstract][Full Text] [Related]
4. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted.
Benet LZ; Larregieu CA
Clin Pharmacol Ther; 2010 Sep; 88(3):405-7. PubMed ID: 20668447
[TBL] [Abstract][Full Text] [Related]
5. ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium.
Bransford P; Cook J; Gupta M; Haertter S; He H; Ju R; Kanodia J; Lennernäs H; Lindley D; Polli JE; Wenning L; Wu Y
Mol Pharm; 2020 Feb; 17(2):361-372. PubMed ID: 31846335
[TBL] [Abstract][Full Text] [Related]
6. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
Davit BM; Kanfer I; Tsang YC; Cardot JM
AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
[TBL] [Abstract][Full Text] [Related]
7. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
[TBL] [Abstract][Full Text] [Related]
8. The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver?
Blume HH; Schug BS
Eur J Pharm Sci; 1999 Dec; 9(2):117-21. PubMed ID: 10620723
[TBL] [Abstract][Full Text] [Related]
9. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
Lennernäs H; Abrahamsson B
J Pharm Pharmacol; 2005 Mar; 57(3):273-85. PubMed ID: 15807982
[TBL] [Abstract][Full Text] [Related]
10. Statistics on BCS classification of generic drug products approved between 2000 and 2011 in the USA.
Nair AK; Anand O; Chun N; Conner DP; Mehta MU; Nhu DT; Polli JE; Yu LX; Davit BM
AAPS J; 2012 Dec; 14(4):664-6. PubMed ID: 22718306
[TBL] [Abstract][Full Text] [Related]
11. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards.
Löbenberg R; Amidon GL
Eur J Pharm Biopharm; 2000 Jul; 50(1):3-12. PubMed ID: 10840189
[TBL] [Abstract][Full Text] [Related]
12. Scientific perspectives on extending the provision for waivers of in vivo bioavailability and bioequivalence studies for drug products containing high solubility-low permeability drugs (BCS-Class 3).
Stavchansky S
AAPS J; 2008 Jun; 10(2):300-5. PubMed ID: 18512159
[TBL] [Abstract][Full Text] [Related]
13. Biopharmaceutics classification system-based biowaivers for generic oncology drug products: case studies.
Tampal N; Mandula H; Zhang H; Li BV; Nguyen H; Conner DP
AAPS PharmSciTech; 2015 Feb; 16(1):5-9. PubMed ID: 25245330
[TBL] [Abstract][Full Text] [Related]
14. Biopharmaceutics classification system: the scientific basis for biowaiver extensions.
Yu LX; Amidon GL; Polli JE; Zhao H; Mehta MU; Conner DP; Shah VP; Lesko LJ; Chen ML; Lee VH; Hussain AS
Pharm Res; 2002 Jul; 19(7):921-5. PubMed ID: 12180542
[TBL] [Abstract][Full Text] [Related]
15. [Biopharmaceutical classification system--experimental model of the prediction of drug bioavailability].
Golovenko NIa; Borisiuk IIu
Biomed Khim; 2008; 54(4):392-407. PubMed ID: 18988456
[TBL] [Abstract][Full Text] [Related]
16. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
[TBL] [Abstract][Full Text] [Related]
17. Use of the Biopharmaceutical Classification System in early drug development.
Ku MS
AAPS J; 2008; 10(1):208-12. PubMed ID: 18446521
[TBL] [Abstract][Full Text] [Related]
18. Solubility Determination of Active Pharmaceutical Ingredients Which Have Been Recently Added to the List of Essential Medicines in the Context of the Biopharmaceutics Classification System-Biowaiver.
Plöger GF; Hofsäss MA; Dressman JB
J Pharm Sci; 2018 Jun; 107(6):1478-1488. PubMed ID: 29421214
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence requirements in the European Union: critical discussion.
García-Arieta A; Gordon J
AAPS J; 2012 Dec; 14(4):738-48. PubMed ID: 22826032
[TBL] [Abstract][Full Text] [Related]
20. Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System.
Bou-Chacra N; Melo KJC; Morales IAC; Stippler ES; Kesisoglou F; Yazdanian M; Löbenberg R
AAPS J; 2017 Jul; 19(4):989-1001. PubMed ID: 28516359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
